Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Capricor Therapeutics (CAPR) over the last 16 years, with Q3 2025 value amounting to $6950.0.

  • Capricor Therapeutics' Cash from Financing Activities fell 9998.97% to $6950.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 1442.96%. This contributed to the annual value of $152.8 million for FY2024, which is 49723.24% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Cash from Financing Activities of $6950.0 as of Q3 2025, which was down 9998.97% from $19580.0 recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Cash from Financing Activities registered a high of $81.1 million during Q4 2024, and its lowest value of $3895.0 during Q1 2023.
  • Its 5-year average for Cash from Financing Activities is $10.7 million, with a median of $1.9 million in 2022.
  • As far as peak fluctuations go, Capricor Therapeutics' Cash from Financing Activities soared by 5869958.92% in 2024, and later tumbled by 9998.97% in 2025.
  • Capricor Therapeutics' Cash from Financing Activities (Quarter) stood at $42370.0 in 2021, then soared by 6861.35% to $2.9 million in 2022, then skyrocketed by 685.45% to $23.2 million in 2023, then surged by 250.01% to $81.1 million in 2024, then plummeted by 99.99% to $6950.0 in 2025.
  • Its last three reported values are $6950.0 in Q3 2025, $19580.0 for Q2 2025, and $50354.0 during Q1 2025.